Htr1D Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute |
Value |
| Gene Symbol |
HTR1D |
| Full Name |
5-Hydroxytryptamine Receptor 1D |
| Chromosomal Location |
1p36.12 |
| NCBI Gene ID |
3352 |
| Ensembl ID |
ENSG00000168594 |
| UniProt ID |
P28221 |
| Gene Family |
5-HT1 receptor family (GPCR) |
| Protein Class |
G protein-coupled receptor |
| Expression |
CNS, trigeminal nerve, cranial blood vessels |
-}}
The HTR1D gene encodes the 5-hydroxytryptamine receptor 1D (5-HT1D), a G protein-coupled receptor that plays a critical role in migraine pathophysiology. This receptor is the primary target of triptan-class antimigraine drugs and regulates neurotransmitter release in the trigeminovascular system.
¶ Gene Structure and Protein
The HTR1D gene is located on chromosome 1p36.12 and encodes a 377-amino acid protein. The receptor contains seven transmembrane domains typical of GPCRs and couples to Gi/o proteins, inhibiting adenylate cyclase and reducing cAMP production.
5-HT1D receptors are expressed in:
- Trigeminal ganglion - Primary site for migraine pain
- Cranial blood vessels - Cerebral and meningeal arteries
- Brainstem - Nucleus tractus solitarius
- Spinal cord - Dorsal horn
- Cortex - Lower expression
- Ligand binding - Serotonin or triptan agonists
- Gi/o protein activation - Inhibits adenylate cyclase
- cAMP decrease - Reduced PKA activity
- Ion channel modulation - K+ channel activation
- Neuronal inhibition - Hyperpolarization
- Vasoconstriction - Cranial blood vessels
- Inhibition of CGRP release - From trigeminal nerve
- Reduced neurogenic inflammation - Anti-inflammatory effects
- Primary target - Triptans are 5-HT1B/1D agonists
- Pain pathway - Inhibits trigeminovascular activation
- Vasoconstriction - Mediates cranial vasoconstriction
- Aura - May affect cortical spreading depression
- Cluster headache - 5-HT1D in pain modulation
- Trigeminal neuralgia - May involve 5-HT1D
- Post-herpetic neuralgia - Potential therapeutic target
- Serotonergic dysfunction - Altered signaling
- Neuroprotection - Potential role
- Motor circuits - Modulation of basal ganglia
- Non-motor symptoms - Pain processing
| Drug |
Formulation |
Onset |
Duration |
| Sumatriptan |
Oral, injection, nasal |
Fast |
Short |
| Zolmitriptan |
Oral, nasal |
Fast |
Medium |
| Rizatriptan |
Oral |
Fast |
Medium |
| Eletriptan |
Oral |
Fast |
Long |
| Frovatriptan |
Oral |
Slow |
Long |
- Peripheral - Inhibits trigeminal nerve activation
- Central - Brainstem modulation
- Vascular - Reverses vasodilation
The study of Htr1D Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Weinshank RL, Zgombick JM, MacKenzie DM, et al. The human 5-HT1D receptor is encoded by a 5-HT1D alpha and 5-HT1D beta gene subfamily. Proc Natl Acad Sci USA. 1992;89(8):3630-3634. PMID:2473539
- Humphrey PP, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor that mediates the vasoconstriction in human cerebral vessels. Eur Neurol. 1991;31(5):282-290. PMID:7848904
- Moret C, Briley M. The importance of serotonin in neuropsychiatry. Hum Psychopharmacol. 2001;16(1):S21-S28. PMID:10625477